Literature DB >> 29255210

Spondyloarthropathies: Tofacitinib shows promise in PsA trials.

Sarah Onuora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29255210     DOI： 10.1038/nrrheum.2017.183

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

Authors:  Dafna Gladman; William Rigby; Valderilio F Azevedo; Frank Behrens; Ricardo Blanco; Andrzej Kaszuba; Elizabeth Kudlacz; Cunshan Wang; Sujatha Menon; Thijs Hendrikx; Keith S Kanik
Journal:  N Engl J Med       Date:  2017-10-19       Impact factor: 91.245

2.  Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Authors:  Philip Mease; Stephen Hall; Oliver FitzGerald; Désirée van der Heijde; Joseph F Merola; Francisco Avila-Zapata; Dorota Cieślak; Daniela Graham; Cunshan Wang; Sujatha Menon; Thijs Hendrikx; Keith S Kanik
Journal:  N Engl J Med       Date:  2017-10-19       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.